24 completed, 2 active not recruiting. 21 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 21 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Active not recruiting 2, Completed 1 |
Follow milvexian: new trials by email Literature Review of milvexian trials Research Report on milvexian
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation Milvexian, Apixaban, Placebo - Atrial Fibrillation | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 20284 | 2023-04-11 | 2026-11-03 |
| A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome Milvexian, Placebo - Acute Coronary Syndrome | Phase 3 | Completed | Janssen Research & Development, LLC | 14194 | 2023-04-07 | 2026-07-06 |
| A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE Milvexian, Placebo - Ischemic Stroke; Ischemic Attack, Transient | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 12523 | 2023-02-15 | 2026-09-25 |
| A Study of Milvexian in Healthy Adult Females Milvexian, Midazolam, Ethinylestradiol - Healthy Female | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 20 | 2023-01-25 | 2025-03-30 |
| A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants BMS-986177 Oral Solution, [14C]BMS-986177 Solution for Infusion, BMS-986177 Spray-dried Dispersion Capsules - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 17 | 2021-07-16 | 2023-08-21 |
| A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants Milvexian, Atorvastatin - Healthy | Phase 1 | Completed | Janssen Pharmaceutica N.V., Belgium | 23 | 2021-06-07 | 2025-03-30 |
| A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants Milvexian - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 115 | 2021-04-14 | 2025-05-23 |
| A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants JNJ-70033093 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 40 | 2021-03-08 | 2025-03-30 |
| A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants Milvexian, 4-Factor Prothrombin Complex Concentrate (4F-PCC), Recombinant Human Factor VIIa (rFVIIa) - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 52 | 2020-07-27 | 2025-08-15 |
| A Study of JNJ-70033093 in Healthy Participants JNJ-70033093 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 24 | 2020-06-26 | 2025-03-30 |
| A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants JNJ-70033093, Placebo - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 66 | 2020-01-10 | 2025-04-27 |
| A Study of JNJ-70033093 and Digoxin in Healthy Participants JNJ-70033093, Digoxin - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 30 | 2020-01-09 | 2025-03-30 |
| A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery JNJ-70033093 25 mg, JNJ-70033093 50 mg, JNJ-70033093 100 mg - Arthroplasty, Replacement, Knee | Phase 2 | Completed | Janssen Research & Development, LLC | 1242 | 2019-06-17 | 2025-03-30 |
| Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants BMS-986177 - Thrombosis | Phase 1 | Completed | Bristol-Myers Squibb | 9 | 2019-05-02 | 2019-10-04 |
| A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel BMS-986177, Placebo, Clopidogrel - Acute Ischemic Stroke, Transient Ischemic Attack (TIA) | Phase 2 | Completed | Bristol-Myers Squibb | 2366 | 2019-01-27 | 2023-06-12 |
| A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects BMS-986177, Placebo (for BMS-986177), Clopidogrel - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 113 | 2018-10-04 | 2021-09-29 |
| Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants BMS-986177 - Thrombosis | Phase 1 | Completed | Bristol-Myers Squibb | 26 | 2018-03-01 | 2018-11-14 |
| Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants BMS-986177 - Thrombosis | Phase 1 | Completed | Bristol-Myers Squibb | 12 | 2017-11-15 | 2018-03-14 |
| An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants Aspirin, BMS-986177, Placebo - Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 20 | 2017-10-18 | 2018-01-19 |
| Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment BMS-986177 - Thrombosis | Phase 1 | Completed | Bristol-Myers Squibb | 24 | 2017-07-13 | 2022-06-10 |
Showing 20 of 26. Sign in to see all of them.
Thrombosis (9) · Ischemic Stroke (2) · Acute Coronary Syndrome (1) · Atrial Fibrillation (1) · Ischemic Attack, Transient (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · Stroke (1)
Bristol-Myers Squibb (14) · Janssen Research & Development, LLC (10) · Janssen Pharmaceutica N.V., Belgium (2)
United States (15) · Belgium (10) · United Kingdom (6) · Argentina (5) · Brazil (5) · Canada (5) · China (5) · Greece (5) · Hungary (5) · Israel (5) · Italy (5) · Japan (5) · Poland (5) · Spain (5) · Australia (4)
PMID 38038437, PMID 34780683, PMID 35262846, PMID 35641780, PMID 35906349, PMID 36564395, PMID 38101902, PMID 39025971, PMID 39214801, PMID 39986336, PMID 41791675, PMID 42440100, PMID 42670965
2019 (2), 2015 (1), 2018 (1)